You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Effectiveness of Adalimumab (HUMIRA®)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Volunteers Trial (ABP 501, Adalimumab)

Completed
  • Healthy Volunteers
  • (no location specified)
Aug 9, 2023

Plaque Psoriasis Trial in Russian Federation (Adalimumab, Humira)

Not yet recruiting
  • Plaque Psoriasis
  • Barnaul, Russian Federation
  • +8 more
Aug 21, 2023

Mild to Moderate COVID-19 Trial (Adalimumab, Placebo)

Withdrawn
  • Mild to Moderate COVID-19
  • (no location specified)
Mar 2, 2022

Disease Activity and Adverse Events of Adalimumab in Chinese

Recruiting
  • Polyarticular Juvenile Idiopathic Arthritis
    • Wuhan, Hubei, China
    • +1 more
    Nov 30, 2022

    Plaque Psoriasis Trial in Beijing (HLX03, adalimumab)

    Completed
    • Plaque Psoriasis
    • Beijing, China
      Peking University People's Hospital
    May 4, 2022

    Healthy Trial in Saint-Petersburg (Adalimumab (BCD-057), Adalimumab (Humira))

    Completed
    Has Results
    • Healthy
    • Adalimumab (BCD-057)
    • Adalimumab (Humira)
    • Saint-Petersburg, Russian Federation
      LLC BioEk
    Oct 8, 2021

    Healthy Volunteers Trial in Madrid (PBP1502, EU-licensed Humira, US-licensed Humira)

    Recruiting
    • Healthy Volunteers
    • Madrid, Spain
      Unidad de Fase I. U. Autonoma de Madrid (Clinical Trials Unit, U
    Sep 26, 2022

    Healthy Volunteers Trial in Antwerp (BMO-2, EU-Humira, US-Humira)

    Completed
    • Healthy Volunteers
    • BMO-2
    • +2 more
    • Antwerp, Belgium
      SGS Belgium NV
    Mar 9, 2022

    Healthy Trial in Merksem (Adalimumab, Lipopolysaccharide (LPS))

    Recruiting
    • Healthy
    • Merksem, Belgium
      Clinical Pharmacology Unit
    May 22, 2023

    Patients Switching FromLow To High Concentration Adalimumab

    Recruiting
    • Crohn Disease
    • +6 more
    • AVT02 (Alvotech Biosimilar to Adalimumab)
    • Montréal, Quebec, Canada
      JAMP Pharma Corporation
    Jun 13, 2023

    Crohn's Disease Trial in Chicago (Vedolizumab, Adalimumab, Ustekinumab)

    Not yet recruiting
    • Crohn's Disease
    • Chicago, Illinois
      University of Chicago Medicine
    Sep 13, 2023

    Uveitis Trial in Sohag (Humira)

    Recruiting
    • Uveitis
    • Sohag, Egypt
      Sohag university
    Jan 4, 2023

    Immune System Disorder Trial in Chang Chun (HLX03, adalimumab)

    Completed
    • Immune System Disorder
    • Chang Chun, Jilin, China
      the 1st affiliated hospital of Jilin University
    May 4, 2022

    Pharmacokinetics, Safety, Efficacy Trial in Dhaka (Advixa (Adalimumab))

    Recruiting
    • Pharmacokinetics
    • +3 more
    • Advixa (Adalimumab)
    • Dhaka, Bangladesh
      ideSHi
    Jul 6, 2022

    Application of N-of-1 Rheumatoid Arthritis

    Not yet recruiting
    • Arthritis, Rheumatoid
    • Boston, Massachusetts
      Tufts Medical Center
    Aug 24, 2023

    Subcutaneous HUMIRA Injection to Assess Adverse Events and

    Recruiting
    • Crohn's Disease
      • Beijing, Beijing, China
      • +8 more
      Jan 12, 2023

      Pyoderma Gangrenosum Trial in Stanford (Humira)

      Withdrawn
      • Pyoderma Gangrenosum
      • Stanford, California
        Stanford University
      Feb 3, 2022

      Sarcoidosis, Cutaneous Sarcoidosis Trial in Stanford (Humira)

      Withdrawn
      • Sarcoidosis
      • Cutaneous Sarcoidosis
      • Stanford, California
        Stanford University
      Feb 3, 2022

      Psoriasis Trial in Saint Petersburg (BCD-057, Humira®)

      Completed
      • Psoriasis
      • BCD-057
      • Humira®
      • Saint Petersburg, Strelna, Russian Federation
        BIOCAD
      Sep 6, 2021

      Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI Trial in Torrance (Adalimumab Injection [Humira],

      Recruiting
      • Mucopolysaccharidosis I
      • +2 more
      • Adalimumab Injection [Humira]
      • Saline Solution for Injection
      • Torrance, California
        The Lundquist Institute at Harbor-UCLA Medical Center
      Aug 9, 2022

      Plaque Psoriasis Trial in Lithuania, Poland (Humira (Adalimumab), SB5 (Adalimumab Biosimilar))

      Recruiting
      • Plaque Psoriasis
      • Humira (Adalimumab)
      • SB5 (Adalimumab Biosimilar)
      • Kaunas, Lithuania
      • +16 more
      Aug 19, 2022

      Disease Activity in Children Population of Juvenile Arthritis

      Completed
      • Polyarticular Juvenile Arthritis
        • Ufa, Bashkortostan, Respublika, Russian Federation
        • +13 more
        Aug 25, 2021

        Psoriasis Trial in Xi'an (SCT630, Adalimumab)

        Active, not recruiting
        • Psoriasis
        • SCT630
        • Adalimumab
        • Xi'an, Shaanxi, China
          First Affiliated Hospital of Fourth Military Medical University
        Jan 26, 2021

        Non-infectious Intermediate Posterior- or Pan-uveitis Trial in China (Adalimumab)

        Recruiting
        • Non-infectious Intermediate Posterior- or Pan-uveitis
        • Beijing, Beijing, China
        • +7 more
        Dec 6, 2022

        Crohn's Disease Trial in Petach Tikva (Adalimumab)

        Completed
        • Crohn's Disease
        • Petach Tikva, Israel
          Schneider Children's Hospital
        Sep 25, 2021